This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? […]
The Answers are in the Crowd? (Part 2) [live from #bio2013] Read Post »
This infographic shows the pharmaceutical companies that listed the most patents last year. The companies with the most drug patents
Which Drug Companies Listed the Most Patents Last Year Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…
Cancer remains the dominant disease target for biotech through to 2010 Read Post »
This is a guest post by Morrison & Foerster‘s Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have
I will be at BIO 2013, representing BiotechBlog, the Journal of Commercial Biotechnology, and Scientific American Worldview. I look forward
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The SEC’s enforcement programme on biotechnology’s communications with the investment community
Go to paperABSTRACT: The proliferation of biotechnology star…
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
This guest post is from the BiotechBlog Intern, Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin
Will the UK be the Goose that Lays The Golden Access? Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Taking stock in biotechnology futures
Go to paperABSTRACT: Investors now have a new tool to help them manage the risk associated with biotechnology investm…
Journal of Commercial Biotechnology Vol 19, Issue 2 (2013) Capturing Value G. Steven Burrill Today’s pressure on pharmaceutical companies reflects
Get new actionable insights and updates from BiotechBlog
